Orexigen Therapeutics
 | |
| Company type | Public |
|---|---|
| Nasdaq: OREX | |
| Founded | 2002 |
| Founder | Eckard Weber |
| Headquarters | La Jolla, California, U.S. |
| Website | orexigen |
Orexigen Therapeutics, Inc. is a public American pharmaceutical company focused on development of treatments for obesity.[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.[1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.[1]
The company has a single product, Contrave, approved for use in the United States in 2014.[2][3] Contrave was designed not only to curb hunger but also reduce cravings.[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.[2][unreliable source?]
Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.[4][5]
References
[edit]- ^ a b c "OREX Key Statistics". MarketWatch. Retrieved 12 September 2014.[dead link]
- ^ a b Osborne, Spencer (7 October 2014). "Orexigen On A Tear - In The Wrong Direction". Seeking Alpha.
- ^ a b "Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals". BioSpace. Retrieved 2020-06-15.
- ^ "U.S. drugmaker Orexigen files for Chapter 11 bankruptcy". Reuters. 2018-03-12. Retrieved 2019-07-30.
- ^ "No magic pill for obesity: Orexigen files for bankruptcy". BioPharma Dive. Retrieved 2020-06-15.
 | This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it. |